Serono Breokinase
Executive Summary
Approval of urokinase for injection withdrawn "without prejudice" by FDA in response to Serono's October 2000 request that the NDA be withdrawn. Serono told FDA that it "neither intends to market the product in the United States nor [to] export it." The pulmonary embolism treatment was never marketed, Serono said